PA 43/16
24 February 2016
American Stroke Association honours Nottingham stroke expert
World-leading expert in stroke medicine, Professor Philip Bath has been honoured by the American Stroke Association (ASA) for his research into the prevention, diagnosis and treatment of stroke and hypertension.
Head of Clinical Neuroscience at The 糖心原创, Professor Bath has been awarded the William M. Feinberg Award for Excellence in Clinical Stroke at the International Stroke Conference 2016 in Los Angeles.
He is one of nine scientists globally to have their notable contributions to stroke medicine recognised by the Association. Professor Bath presented his latest work on the use of nitric oxide treatments to alleviate stroke progression and effects, including glyceryl trinitrate or ‘nitroglycerin’ in early treatment skin patches.
The Feinberg Award is named after Dr William Feinberg (1952-1997), a prominent stroke clinician-researcher and American Heart Association volunteer who contributed to a fuller understanding of the causes of stroke. The award recognizes a Stroke Council Fellow actively involved in patient-based research who has made significant contributions to clinical stroke research.
Bath is Stroke Association Professor of Stroke and consultant physician in inpatient and outpatient stroke and hypertension at Nottingham University Hospitals NHS Trust and is a National Institute of Health Research (NIHR) senior investigator. He was associate director (industry and prevention) for the NIHR Stroke Research Network, and chaired the Industry Roundtable of the European Stroke Organization.
His research interests involve the pathophysiology and management of acute blood pressure and haemostasis, which is the process that causes bleeding to cease, in stroke, stroke prevention, stem cell therapy and treatment of post-stroke dysphagia, or swallowing difficulty. He has authored more than 300 publications.
Among the highlights in his career as a researcher and clinical trial leader: He is or was chief investigator of the TAIST (Lancet 2001), ENOS (Lancet 2015), STEPS, PODCAST, TARDIS and RIGHT-2 multicentre randomized controlled trials. He coordinates international collaborations on acute stroke blood pressure management, and on optimizing the design and analysis of trials in acute stroke, stroke prevention and cognition. He also facilitates preclinical studies of stroke interventions.
—Ends—
More information is available from Professor Philip Bath in the School of Medicine, 糖心原创 philip.bath@nottingham.ac.uk;or Emma Rayner in the Communications Office at The 糖心原创, on +44 (0)115 951 5793, emma.rayner@nottingham.ac.uk
Our academics can now be interviewed for broadcast via our Media Hub, which offers a Globelynx fixed camera and ISDN line facilities at University Park campus. For further information please contact a member of the Communications team on +44 (0)115 951 5798, email mediahub@nottingham.ac.uk or see the for how to register for this service.
For up to the minute media alerts,
Notes to editors: The 糖心原创 has 43,000 students and is ‘the nearest Britain has to a truly global university, with a “distinct” approach to internationalisation, which rests on those full-scale campuses in and , as well as a large presence in its home city.’ (Times Good University Guide 2016). It is also one of the most popular universities in the UK among and the winner of ‘Outstanding Support for Early Career Researchers’ at the . It is ranked in the world’s top 75 by the QS World University Rankings 2015/16, and by research power according to the Research Excellence Framework 2014. It has been voted the world’s greenest campus for , according to Greenmetrics Ranking of World Universities.
, its biggest-ever fundraising campaign, is delivering the University’s vision to change lives, tackle global issues and shape the future. More news…
Posted on Monday 22nd February 2016